- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07946926
Adaptation of Facilitated Access to Mutual Aid for Community Alcohol and Drug Services (FAMA)
Adaptation of a Facilitated Access to Mutual Aid (FAMA) Intervention for Adults Accessing Community Alcohol and Drug Services in England.
Alcohol and other drug (AOD) use disorders are associated with a range of adverse outcomes. Relapse following AOD treatment is common. Attendance at Mutual Aid Groups (MAGs) is associated with improved health outcomes and reduced healthcare utilisation costs. National guidance recommends that clinical staff promote MAG attendance, but few patients are referred to, or attend, MAGs. An intensive referral intervention, developed in the United States of America has been shown to increase engagement with MAGs. The aim of this National Institute for Health Research (NIHR)-funded study is to adapt and test a Facilitated Access to Mutual Aid (FAMA) intervention and staff training for delivery in community AOD services in England.
Phase one of this study consists of qualitative focus groups conducted with staff of community AOD services and adults receiving AOD treatment. Eight focus groups will explore participants' views of MAGs and the existing American FAMA intervention. The FAMA intervention will then be adapted and staff training developed, based on the focus group findings and input from patient and public involvement and engagement (PPIE) groups.
Phase two of this study consists of testing the adapted FAMA intervention. Staff in one community AOD service will receive the newly developed FAMA training. They will deliver FAMA to people who are currently receiving AOD treatment service. Each session will be recorded and the fidelity of intervention delivery will be assessed by the research team using a checklist. Staff and patient feedback will be collected using brief questionnaires in informal feedback sessions. The FAMA intervention will be refined and delivered again with another round of feedback being collected. A final version of the FAMA intervention will then be agreed by the research team and PPIE groups.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Odhadovaný)
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Adults aged 18+ years who are accessing AOD treatment and staff, aged 18+ years who are working in paid client facing role in an AOD treatment service.
Popis
Phase one (staff) inclusion criteria:
- Aged 18+ years
- Currently working in a paid client facing role in an AOD treatment service
Phase one (people accessing AOD treatment) inclusion criteria:
- Aged 18+ years
- Currently receiving treatment from an AOD treatment service
Phase two (staff) inclusion criteria:
- Aged 18+ years
- Currently working as a keyworker or recover worker in an AOD treatment service
Phase two (people accessing AOD treatment) inclusion criteria:
- Aged 18+ years
- Currently receiving treatment from an AOD treatment service
- On a participating staff member's caseload
- Not attending MAGs.
Exclusion Criteria:
- N/A
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: OTHER
- Časové perspektivy: CROSS_SECTIONAL
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Qualitative focus groups
Časové okno: Focus groups will last approximately 90 minutes
|
Qualitative focus groups |
Focus groups will last approximately 90 minutes
|
|
Acceptability of Intervention measure (AIM) adapted for FAMA
Časové okno: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be acceptable |
Maximum 10 weeks from enrolment in the study
|
|
Feasibility of Intervention (FIM) adapted for FAMA
Časové okno: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be feasible |
Maximum 10 weeks from enrolment in the study
|
|
Appropriateness Measure (IAM) adapted for FAMA
Časové okno: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be appropriate |
Maximum 10 weeks from enrolment in the study
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- IRAS 370125
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .